Welcome
"Glaucoma - Arrest, Restore & Protect"
The novel, non-damaging laser energy treatments for chronic, degenerative ocular disease.
The Mission
Our Treatment Philosophy
Our Treatment Philosophy
Our Treatment Philosophy
The treatment of preperimetric (suspect) glaucoma is normally deferred until functional and morphologic changes manifest on subjective visual field tests and objective nerve fiber thinning. New, objective electrophysiologic, OCT angiographic, and choroidal profusion mapping diagnostics allow earlier detection of initial functional and
The treatment of preperimetric (suspect) glaucoma is normally deferred until functional and morphologic changes manifest on subjective visual field tests and objective nerve fiber thinning. New, objective electrophysiologic, OCT angiographic, and choroidal profusion mapping diagnostics allow earlier detection of initial functional and anatomic disease indicators. Thus, the opportunity is presented to offer earlier hypotensive and neuroprotective interventions resulting in the preservation of visual function. ALeyeGN has developed novel laser treatments that seek to accomplish these early interventions in an extremely safe and repeatable as-needed manner. This therapy is appropriate for the long-term management of Open-Angle Glaucoma (OAG) and many other chronic, progressive, neurodegenerative retinopathies such as Age-related Macular Degeneration (AMD), Macular Telangiectasia Type 2 (MTT2), Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), Central Serous Chorioretinopathy (CSC).
The Food and Drug Administration has not evaluated the statements made regarding these products. The safety and efficacy of these treatments have not yet been proven in prospective randomized controlled clinical trials or confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure or prevent any disease.
IOP Control
Our Treatment Philosophy
Our Treatment Philosophy
Glaucoma, the world's second leading cause of blindness, is a chronic, degenerative, progressive disease that affects the survival of the retinal ganglion cells (RGC), axons, and synopses to the optic nerve head. Reduction of intraocular pressure (IOP) is the goal of current glaucoma treatments to stop or slow the disease's progression.
Glaucoma, the world's second leading cause of blindness, is a chronic, degenerative, progressive disease that affects the survival of the retinal ganglion cells (RGC), axons, and synopses to the optic nerve head. Reduction of intraocular pressure (IOP) is the goal of current glaucoma treatments to stop or slow the disease's progression. Current glaucoma interventions (medications, surgery, laser, etc.) pursue this goal almost exclusively by targeting IOP reduction, the only known and treatable, modifiable risk factor.
ALeyeGN has developed an easy to administer, fast, safe, painless, automated, and repeatable laser treatment that accomplishes IOP reduction through the non-damaging laser photothermal stimulation of endogenous biochemical stress-responses leading to the restoration of lost IOP homeostasis.
Retinal Neuroprotection
Our Treatment Philosophy
Retinal Neuroprotection
Unfortunately, many glaucoma patients suffer progressive vision loss due to retinal ganglion cell (RGC), axons, and optic nerve damage even when normal or even lower IOP is achieved, controlled, and maintained. Lowering and controlling IOP is not enough. Like many other chronic, degenerative, and progressive retinal diseases, glaucoma i
Unfortunately, many glaucoma patients suffer progressive vision loss due to retinal ganglion cell (RGC), axons, and optic nerve damage even when normal or even lower IOP is achieved, controlled, and maintained. Lowering and controlling IOP is not enough. Like many other chronic, degenerative, and progressive retinal diseases, glaucoma is rooted in a loss of healthy, neurotrophic function, which initiates the cellular apoptotic process. ALeyeGN has developed an automatic, safe, consistent, repeatable, neuroprotective, sub-threshold treatment. A non-damaging micropulse laser induces a panmacular photostimulation of the central retinal pigment epithelium cells (RPE). This is known to restore the natural trophism in the dysfunctional RPE cells in diverse retinal disorders, which, like glaucoma, are chronic, progressive, and neurodegenerative. This restored neurotropism rescues RGCs that are sick but not dead yet, thus preventing, stopping, or slowing down the loss of visual function.
Clinical Trials Underway
ALeyeGN is currently engaged in First-in-Human Trials and will be publishing results as they become available. Interested parties may contact Michael Ballard at mike@ALeyeGN.com or Georgio Dorin at Giorgio@ALeyeGN.com for additional information.
Subscribe
Sign up to hear from us.
ALeyeGN Technology LLC
Copyright © 2023 ALeyeGN Technology LLC - All Rights Reserved.
Powered by GoDaddy